GlassScriptPhysician profile
Fahad Omar
NPI 1821227471
$2,085.35
in general payments reported to CMS, 2019-2025
21 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $145 · 2021: $264 · 2022: $453 · 2023: $212 · 2024: $471 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $397.72 | 2019-2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.42 | 2019-2025 | Ofev |
| Mylan Specialty L.P. | $202.12 | 2019-2024 | Yupelri |
| Philips North America LLC | $195.98 | 2022-2024 | (Ak6) Vest Therapy |
| Astrazeneca Pharmaceuticals LP | $147.20 | 2019-2024 | Airsupra, Fasenra, Tezspire |
| Grifols USA, LLC | $123.79 | 2021-2024 | Prolastin-C Liquid |
| Viatris Specialty LLC | $120.84 | 2025 | Yupelri |
| Genzyme Corporation | $101.35 | 2023-2025 | |
| Insmed, INC. | $96.65 | 2022-2025 | Arikayce |
| E.R. Squibb & Sons, L.L.C. | $45.16 | 2019-2022 | |
| Abbvie INC. | $34.02 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.95 | 2022 | |
| Jazz Pharmaceuticals INC. | $32.63 | 2021 | |
| Gilead Sciences, INC. | $28.24 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $21.29 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $19.92 | 2019 | |
| Chiesi USA, INC. | $19.90 | 2021 | |
| Baxter Healthcare | $19.41 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Harmony Biosciences LLC | $19.30 | 2024 | |
| Vifor Pharma, INC. | $17.56 | 2024 | Zemaira |
| Shire North American Group INC | $16.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahad Omar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.